Trial Profile
Efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2022
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Estramustine (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Nov 2019 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 New trial record